Aziz Sawaf - 20 Feb 2026 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
SVP & CHIEF FINANCIAL OFFICER
Signature
/s/ Brett A Grimaud, Attorney-in-Fact
Issuer symbol
TBPH
Transactions as of
20 Feb 2026
Net transactions value
-$406,412
Form type
4
Filing time
24 Feb 2026, 19:40:51 UTC
Previous filing
24 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sawaf Aziz SVP & CHIEF FINANCIAL OFFICER C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO /s/ Brett A Grimaud, Attorney-in-Fact 24 Feb 2026 0001961289

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Tax liability $406,412 -20,672 -6.1% $19.66 316,123 20 Feb 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.